Why Is ARROWHEAD PHARMACEUT (ARWR) Stock Down Today?
By the Top Tier Newswire AI Desk · September 15, 2026 at 3:26 PM ET · reviewed against 3 wire stories
ARROWHEAD PHARMACEUT (ARWR) is down -11.89% in the latest session. Our newswire has captured 3 stories on ARWR across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why ARWR stock is down today
Arrowhead Pharmaceuticals (ARWR) fell 11.89% to $71.08 on Monday, marking its worst single-day decline in over a year. The stock opened at $80.45 but steadily declined throughout the session, reaching a low of $71.01 before closing near the bottom of the range. The sell-off followed the release of interim clinical data for its first dual-functional RNAi therapeutic for mixed hyperlipidemia, which, despite showing strong reductions in key biomarkers, triggered a sharp negative reaction from investors.
What Happened
Arrowhead announced that its Phase 1/2a study showed mean maximal reductions of 88% in APOC3, 54% in LDL-C, and 73% in triglycerides. The drug also demonstrated a 72% reduction in PCSK9. These results were presented ahead of its appearance at the Morgan Stanley 24th Annual Global Healthcare Conference. However, the market interpreted the data as a "sell the news" event, with the stock reacting poorly despite the scientific promise. Two directors, Perry Michael S and Olukotun Adeoye Y, sold shares on August 18, and the CEO of Citigroup initiated coverage with a Buy rating and $108 price target, which failed to offset the downward pressure.
What The Data Shows
The stock has declined 14.5% over the past eight sessions, from $85.40 to $73.04, and printed 60 fresh 52-week lows on September 15. The session saw heavy volume of 2.4 million shares, more than double the 3-month average. Despite the positive data, the stock remains unprofitable with a TTM EPS of -2.28 and a net margin of -47.8%. Retail traders on r/wallstreetbets are calling the stock oversold, but institutional sentiment appears to be deteriorating, with a 7-day average sentiment score of 55/100, down from 59/100 over the past 30 days.
What To Watch
Arrowhead Pharmaceuticals has no upcoming earnings report scheduled, but coverage breadth and institutional sentiment shifts will be key to watch in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ARWR · today's session (5-min) · -10.97% vs prior close · updated 8:14 PM ETAI sentiment, last 36h · averaged over 3 stories · 54/100 neutral
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
5h agoStocktwits NewsBEARISH 38General
ARWR Stock On Track For Worst Day In Over A Year Despite Positive Early-Stage Data For Cholesterol Drug — Retail Dismisses ‘Sell The News’ Reaction
ARWR had already run hard into the catalyst and remains far above last year’s levels after a 52-week high near $95 in July.
6h agoSeeking AlphaBULLISH 56General
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 11:30 AM EDTCompany ParticipantsDr.
12h agoStockTitanBULLISH 67Product/PR
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
The Phase 1/2a study also found mean maximal reductions of 88% in APOC3, 54% in LDL-C and 73% in triglycerides; multiple-dose safety testing continues.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →